IP Library Granted Patent US 7,141,548
Granted Patent B2
US 7,141,548 · App. 10/861,004 · Granted Nov 28, 2006

Prevention of hyperinsulinemia in subjects undergoing growth hormone (GH) treatment

Assignee: Novo Nordisk A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,141,548
App. No.
10/861,004
Granted
Nov 28, 2006
Kind
B2
Abstract

The present invention provides methods and compositions for preventing hyperinsulinemia that can result from therapeutic administration of growth hormone. The methods are carried out by imposing a restricted high-fat diet and/or by administering one or more drugs that lower serum lipids.

Claims (6)

1. A method for reducing the incidence of a statistically significant rise in plasma insulin levels in an animal or human subject undergoing treatment with growth hormone (GH), comprising providing the subject, during the growth hormone treatment period, with a restricted amount of a high-fat (HF) diet as the sole food source.

2. The method of claim 1 , wherein the energy content of the diet does not exceed the theoretical maintenance level for the subject.

3. The method of claim 2 , wherein the subject is a human.

4. The method of claim 3 , wherein the human is obese.

5. The method of claim 1 , wherein the subject is a human.

6. The method of claim 5 , wherein the human is obese.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2009
From: NOVO NORDISK A/S
To: NOVO NORDISK HEALTHCARE AG
Reel/Frame 022062/0901 →
Priority Claims (1)
DK 2003 00548 · Apr 9, 2003 · national
Continuity (3)
Continuation 1082202000 · Apr 9, 2004
Provisional Application 6046707900 · May 1, 2003
Related Publication 20040220109A1 · Nov 4, 2004